Deleterious BRCA2 sequence variants are over-represented in cases of T-cell Non-Hodgkins lymphoma (NHL) or CLL [see Additional file 1], consistent with a role for BRCA2 in preventing these diseases. This evidence concerns the gene BRCA2 and B-cell chronic lymphocytic leukemia.